Ralph C. Eagle, Jr., MD

Ralph C. Eagle, Jr., MD

Stallard Lecture

Ralph C. Eagle, Jr., MD has served as Director of the Department of Pathology at the Wills Eye Hospital in Philadelphia, Pennsylvania since 1986. He is the Simmonds Professor of Ophthalmic Pathology at Wills and Professor of Ophthalmology at Thomas Jefferson University. Born in the Philadelphia suburbs, Dr. Eagle received his MD degree from the University of Pennsylvania School of Medicine where he completed his ophthalmology residency under Dr. Harold G. Scheie.


Ophthalmic pathology training included fellowships with Dr. Myron Yanoff at the University of Pennsylvania and Drs. Lorenz E. Zimmerman and Ramon Font at the Armed Forces Institute of Pahology in Washington, DC. His honors include the American Ophthalmological Society, the Zimmerman Medal of the AAOOP, the Macula Society’s W. Richard Green Lecture and the International Society of Ophthalmic Pathologists’ Gordon K. Klintworth Lecture. He has served as President of the American Association of Ophthalmic Pathologists. Dr. Eagle is Director of Continuing Medical Education at Wills Eye Hospital. He is a dedicated teacher who has lectured at academic institutions on five continents and the sole author of a popular eye pathology textbook now in its third edition. An avid photographer, he is noted for the quality of his macro and microscopic illustrations of eye disease. He likes to travel and his hobbies include art, photography and fossil collecting.

Professor Francis L. Munier, MD

Francis L. Munier, MD

Judith Kingston Lecture

Francis L. Munier, MD is board certified in Ophthalmology and Medical Genetics. After a fellowship at Children Hospital Los Angeles with Linn Murphree between 1991 and 1993, he joined the Retinoblastoma Clinic at Jules-Gonin Eye hospital and created the first Swiss Unit of Oculogenetics, furthering Franceschetti’s legacy.


His main contributions in the field of Oculogenetics culminated in the identification of TGFBI as the first corneal dystrophy gene, as well as EFEMP1 responsible for Malattia Leventinese, CRYGD causing aculeiform cataract, and HMX1in the context of the oculo-auricular syndrome of Schorderet-Munier-Franceschetti among others.

The management of retinoblastoma patients remains his main focus. In 2012 he published his landmark paper on intravitreal chemotherapy, a therapy which soon spread worldwide saving hundreds of eyes with vitreous disease. At the ARVO meeting 2015, he presented another breakthrough, introducing a new technique of intra-cameral injections of melphalan for the successful management of anterior chamber invasion, considered until now an intractable form of retinoblastoma. Under his guidance, the Lausanne Retinoblastoma Clinics became a tertiary reference center, with more than 50 new patients a year originating from Switzerland (10%), Europe (40%) and abroad (50%).

In 2015, he was appointed Professor Ordinarius and head of Ocular Oncology and Oculogenetics at Jules-Gonin Eye Hospital. He is the author of more than 20 book chapters, 200 peer-reviewed papers cumulating over 6000 citations with an h-index of 40.

Dr Bita Esmaeli

Bita Esmaeli

Dr Bita Esmaeli is a Professor of Ophthalmology in the Department of Plastic Surgery at The University of Texas M. D. Anderson Cancer Center, where she has had an orbital oncology and oncologic ophthalmic plastic surgery practice since 1998.

Dr Esmaeli’s practice focus is surgical treatment of orbital tumors, lacrimal gland carcinomas, eyelid cancers, melanoma of eyelid and conjunctiva, and reconstructive surgery in the periocular region including lacrimal surgery.


Dr Esmaeli has authored over 180 peer-reviewed manuscripts, over 55 invited articles and book chapters, has spearheaded several clinical trials, and has participated in numerous research protocols at M. D. Anderson Cancer Center. She has received many prestigious awards and honors including the Merrill Reeh Pathology Award and the Research Award from the American Society of Ophthalmic Plastic and Reconstructive Surgery, the American Academy of Ophthalmology Senior Achievement Award, Best Doctors in America, and Top Doctors Award. Dr Esmaeli is a member of the American Ophthalmologic Society.

Dr Esmaeli 's research interests include molecular signature of ocular and orbital tumors, tissue banking,  eye and vision-sparing treatment strategies for orbital and adnexal cancers, and ocular side effects of cancer therapy.

Dr. Esmaeli helped establish the Ophthalmology Service as a comprehensive full-time service at M. D. Anderson Cancer Center in 1998. She served as the Director of Service from 1998 to 2001 and the Chief of Ophthalmology from 2001 to 2004. She is the Program Director for an ASOPRS-sponsored fellowship in oculoplastic surgery and orbital oncology at M. D. Anderson Cancer Center. She currently chairs the Graduate Medical Education Committee at MD Anderson Cancer Center.

Victoria Cohen

Victoria Cohen

Victoria Cohen is a full time Ocular Oncologist at Moorfields Eye Hospital, London UK and Director of the Service. Her training in Ocular Oncology began in 1996 when she undertook research Sheffield. She then subsequently undertook two Ocular Oncology fellowships in London in 2003 and 2005. Finally, she undertook a year of Ocular Oncology training in the USA spending time at Wills Eye Hospital. MD Anderson, and Memorial Sloane Kettering. In 2007 she was appointed Consultant Ocular Oncologist and became Director of the London Service in 2009.


Victoria is actively involved in research, teaching and training. She is widely published in the field of Ocular Oncology and a leading author on the UK National Guidelines for the management of Uveal Melanoma, which achieved NICE accreditation in 2015. The London international fellowship program in Ocular Oncology offers highly specialised training in ocular surface and Intra-ocular tumours including retinoblastoma.

Hans E. Grossniklaus MD

Hans E. Grossniklaus MD

F. Phinizy Calhoun Jr. Professor of Ophthalmology and Pathology, Vice-Chairman, Department of Ophthalmology. 

Dr. Grossniklaus received his MD degree from Ohio State University, followed by residencies in ophthalmology and pathology at Case Western Reserve University and fellowships in ophthalmic pathology at the Wilmer Institute and the Armed Forces Institute of Pathology. He is board certified in ophthalmology and pathology.   He has been on the faculty at Emory University and served as director of the L.F. Montgomery Ophthalmic Pathology Laboratory since 1989 and founding director of the Ocular Oncology Service since 2007 where he actively sees patients and performs surgery.


He is a member of numerous national and international organizations, including the Past-President and current Executive Vice President of the American Ophthalmological Society (AOS), Past-President of the American Association of Ocular Oncologists and Pathologists and Verhoeff-Zimmerman Society, and member of Academia Ophthalmological Internationalis (AOI).  He has served on 14 local committees and 5 national/international committees, including NIH NEI and NCI Study Sections.  He is on the editorial board of five journals, including and founding Co-Editor in Chief of Ocular Oncology and Pathology.  He has received support from 11 federally funded grants including being PI with continuous support of NCI ocular oncology grants.  He has served as the structural biology module director of the ophthalmology departmental core grant for over 20 years.  He has received support from eleven private grants.  He has been a visiting professor at 20 institutes including the Massachusetts Eye and Ear Infirmary, Wilmer Institute, Jules Stein Institute, and Wills Eye Hospital.  He has been an invited participant in over 50 national and international conferences including lectures in Australia, Brazil, Germany, Japan, Korea and Sweden.  He has received numerous awards, including the AAO Senior Achievement Award, the outstanding former Heed Fellow Award and the W. Richard Green Lecture Award.  He has authored/co-authored nearly papers published in peer reviewed journals and 12 books/monographs.  As director of the L.F. Montgomery Laboratory, a world premier eye pathology laboratory, he has signed out approximately 60,000 cases.  He has trained 20 fellows from around the world, most of whom now hold academic positions.  He has trained dozens of residents and medical students. He has received three teaching awards and a teaching grant.  His research interests are pathobiology of retinoblastoma and uveal melanoma and local therapies for these tumors.

Professor Georgina Long

Georgina Long

Medical Oncologist, Melanoma Institute Australia 

BSc PhD MBBS FRACP, is Chair of Melanoma Medical Oncology and Translational Research at Melanoma Institute Australia (MIA) and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance.


In recognition of her ground breaking research, Professor Long has received a number of awards, including the prestigious Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research in 2016, and a number of recent CINSW Premier’s Awards for Outstanding Cancer Research: In 2014, she was awarded the Wildfire Award for the most highly-cited, original, peer-reviewed article published in 2011; and in 2013 she was named the Outstanding Cancer Research Fellow.

She is the author of over 120 peer-reviewed publications in clinical and translational research in melanoma since 2011, including the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 120 occasions.  She is Chair of the ASCO Scientific Committee for melanoma and skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.


Nicholas K. Hayward

Nicholas K. Hayward

PhD 1983 Molecular Biology, University of Queensland

Prof. Hayward has studied the molecular genetics of melanoma for 30 years and is a foundation member of the International Melanoma Genetics Consortium (GenoMEL) and the Society for Melanoma Research. His work spans molecular epidemiology, genetics, genomics, cell biology and mouse models of melanoma.


He played key roles in the identification of CDK4, MITF, POT1, ACD and TERF2IP as familial melanoma susceptibility genes. He has also contributed significantly to the majority of genome-wide association studies that have identified numerous low penetrance risk genes for melanoma and the associated phenotypic traits of pigmentation and naevi. His research has contributed to the understanding of key somatic mutations that drive melanocyte neoplasia, including the seminal finding of BRAF mutations in naevi, and MAP3K5, MAP3K9, RASA2 and RAC1 mutations in melanoma. He is currently a principal investigator of the Australian Melanoma Genome Project – an endeavour that aims to characterize the genomic landscape of somatic mutations and chromosomal aberrations in 500 melanomas.

Dr Santosh G Honavar, MD, FACS

Santosh G Honavar, MD, FACS

Director, Medical Services (CFS Group)

Director, CFS Education Director, National Retinoblastoma Foundation

Director, Dept of Ophthalmic Plastic Surgery and Ocular Oncology Centre for Sight


Dr Honavar had his medical education at the Bangalore Medical College. He was the Best Graduate of the Bangalore University. He received residency training in Ophthalmology, followed by fellowship in Ophthalmic Plastic Surgery and Ocular Oncology at the Dr Rajendra Prasad Center for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi. He was adjudged the Best Resident. Dr Honavar further trained in Ocular Oncology and was mentored by Profs JA Shields and CL Shields at the Wills Eye Hospital, Philadelphia, PA, USA. He thereafter established the Ocular Oncology Service at the LV Prasad Eye Institute, Hyderabad, the first such facility in the country. The comprehensive multispecialty Children's Eye Cancer Center that he has established has done pioneering work and is now recognized as one of the best in the World. He currently leads the Medical Services team at the Centre for Sight, and also heads CFS Education. Dr Honavar leads the International Council of Ophthalmology fellowship curriculum development committee and the oculoplasty section of the residency curriculum development committee, while being on its Advisory Board. He is currently the Secretary of the Oculoplastics Association of India and the President of Asia Pacific Society of Ocular Oncology and Pathology.

His research interests comprise of tumors of the ocular surface, orbit and retinoblastoma. Dr Honavar has extensively published in peer reviewed journals (over 200 manuscripts) and has written several book chapters, while being a reviewer for all the major journals in ophthalmology and oncology. Dr Honavar's overall research contributions that have had very significant impact on the diagnosis and management of retinoblastoma and its outcome.

Some of the major awards and honors to his credit include seven Gold Medals and the Best Graduate Award by the Bangalore University for excellence in MBBS, 1988; Col Rangachari Gold Medal by the AIOS, 1992; Best Resident Award by the Dr Rajendra Prasad Center for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, 1995; ARVO-Santen International Fellowship by the ARVO, 1996; Zeigler International Fellowship by the Orbis International, New York, USA, 1999; Young Scientist Award by the Indian Society of Oncology, 2000; Best of Show Award for the video film by the American Academy of Ophthalmology, 2002 and 2006; Achievement Award by the American Academy of Ophthalmology, 2002; Dr Siva Reddy International Award by the AIOS, 2007, Shanti Swarup Bhatnagar Award by the Government of India, 2010, Prof MA Matin Award by the Bangladesh Academy of Ophthalmology, 2013 and Jerry Shields International Award by APAO, November 2013.

Dr Mark Shackleton

Mark Shackleton

Dr Mark Shackleton is a Medical Oncologist and Head of the Cancer Development and Treatment Laboratory at Peter MacCallum Cancer Centre.  After training in medical oncology in Melbourne and at the Ludwig Institute for Cancer Research, Dr Shackleton undertook his PhD at the Walter and Eliza Hall Institute for Medical Research, and postdoctoral work at the University of Michigan, USA.  


A winner of multiple research awards, Dr Shackleton is also a current Victorian Cancer Agency Clinical Research Fellow, a Director of the Victorian Endowment for Science, Knowledge and Innovation and a Board Member of the Australian and New Zealand Melanoma Trials Group. His laboratory at Peter Mac focuses on understanding mechanisms of cancer initiation, propagation and treatment response/resistance.

Richard A Scolyer

Richard A Scolyer

Consultant Pathologist, Melanoma Institute Australia

Consultant Pathologist and Co-Director of Research, Melanoma Institute Australia

Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney

Clinical Professor, Sydney Medical School, The University of Sydney

National Health and Medical Research Council Practitioner Fellow


Richard Scolyer studied medicine at the University of Tasmania (BMedSci, MBBS). After completing clinical training in Australia and overseas, he undertook pathology training at the Canberra Hospital and at the Royal Prince Alfred Hospital leading to Fellowship of the Royal College of Pathologists of Australasia. Richard is currently Consultant Pathologist and Co-Director of Research, Melanoma Institute Australia; Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney; and Clinical Professor, The University of Sydney.

Richard has presented on more than 150 occasions at conferences throughout the world, and is a co-author of more than 400 articles and book chapters on melanocytic pathology and related research. In 2006, Richard was awarded the degree of Doctor of Medicine by The University of Sydney for his thesis of publications on melanocytic pathology. He received a NSW Premier's Award for Outstanding Cancer Research in 2009 and 2012. He is also an editorial board member of the American Journal of Surgical Pathology, a member of the International Editorial Advisory Board of Histopathology and Senior Associate Editor of Pathology. In 2013, Richard was appointed Vice Chair of the Melanoma Expert Panel of the American Joint Committee on Cancer (AJCC) for the 8th edition of their Cancer Staging System. He is currently President-Elect of the Australasian Division of the International Academy of Pathology. Together with other MIA colleagues, Richard is chief investigator on 5 year program grants from both the NHMRC and CINSW and he also has a personal Fellowship from the NHMRC.

Jerry A. Shields, M.D.

Jerry A. Shields, M.D.

Jerry A. Shields, M.D. is director of Oncology Service at Wills Eye Hospital in Philadelphia. He was a founder and first president of ISOO. He has authored or co-authored  1364 articles in scientific journals and  616 textbook chapters. He has given 1560 lectures including 82 named lectures.  In 2012, he was honored by the establishment of the Jerry Shields Lecture presented annually at the Asian Pacific Society of Ophthalmology.


In March 2013 he received the National Physician of the year award (named top doctor in America) by Castle Connolly Medical LTD. He was 2014 recipient of the annual Laureate Award. This is most prestigious honor given to one person annually by the American Academy of Ophthalmology.

Dr. Shields is married to Dr. Carol L. Shields M.D. who has also received numerous academic honors and awards. They have 7 children ranging from 28 to 16 years of age.

Professor John Thompson

John Thompson

Executive Director, Melanoma Institute Australia

John Thompson has been Professor of Melanoma and Surgical Oncology at the University of Sydney since 1999. He was Executive Director of Melanoma Institute Australia (formerly the Sydney Melanoma Unit), one of the world's largest melanoma treatment and research centres, from 1998 to 2016. He has been a pioneer of the sentinel lymph node biopsy procedure, and developed the isolated limb infusion technique for melanoma. He is an Honorary Fellow of the American Surgical Association, an Honorary Fellow of the American College of Surgeons, and a Fellow of the Australian Academy of Health and Medical Sciences.


Professor Thompson is author of over 700 peer-reviewed scientific articles, as well as the editor of several books and the author of numerous book chapters, review articles and monographs. In 2014 he was made an Officer of the Order of Australia (AO) for distinguished service to medicine in the field of oncology research, particularly melanoma, to international and national professional organisations, and to medical education.

Dr Anthony Joshua

Anthony Joshua

Dr Anthony Joshua completed his medical oncology training at the Royal Prince Alfred hospital in Sydney, Australia before moving to Toronto, Canada to complete a PhD prostatic carcinogenesis, and a clinical Fellowship in Melanoma and Genito-urinary malignancy.


He joined the Department of Medical Oncology at Princess Margaret Cancer Centre in Toronto as a staff oncologist in late 2008, specialising in prostate cancer and melanoma with research interests in circulating tumour DNA, tumour heterogeneity, mechanisms of hormone resistance and autophagy. He has contributed to major clinical trials in uveal melanoma and recently completed the first global meta-analysis of uveal melanoma clinical trials. He returned to Australia, joining the Kinghorn Cancer Centre and the Garvan Institute of Medical Research in late 2015. He is currently a conjoint Associate Professor with the University of New South Wales.


© Copyright 2015. Site by Invisage